Norris Cotton Cancer CenterNorris Cotton Cancer Center
In This Section
A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients with B-cell Non-Hodgkin Lymphoma (NHL)
Principal Investigator (?)
Lansigan, Frederick
Study Number
An open-label, dose-escalation trial of the safety, tolerability, pharmacokinetics (PK), biological, and clinical activity of DI-Leu16-IL2 administered to patients with CD20 (B-lymphocyte antigen CD20) positive Non-Hodgkin Lymphoma (NHL) that have failed standard rituximab-containing therapy. Following peripheral blood B cell depletion with rituximab (if needed) each patient will receive DI-Leu16-IL2 administered as a subcutaneous (SC) injection for three consecutive days every three weeks. 
Phase (?)
Phase III
Sponsor (?)

Darcie Findley

Available at the following location(s)


View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.